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Background: The COVID-19 pandemic, caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has placed a significant demand on healthcare providers
(HCPs) to provide respiratory support for patients with moderate to severe symptoms.
Continuous Positive Airway Pressure (CPAP) non-invasive ventilation can help patients
with moderate symptoms to avoid the need for invasive ventilation in intensive care.
However, existing CPAP systems can be complex (and thus expensive) or require high
levels of oxygen, limiting their use in resource-stretched environments.
Technical Development + Testing: The LeVe (“Light”) CPAP system was developed
using principles of frugal innovation to produce a solution of low complexity and high
resource efficiency. The LeVe system exploits the air flow dynamics of electric fan blowers
which are inherently suited to delivery of positive pressure at appropriate flow rates for
CPAP. Laboratory evaluation demonstrated that performance of the LeVe system was
equivalent to other commercially available systems used to deliver CPAP, achieving a
10 cm H2O target pressure within 2.4% RMS error and 50–70% FiO2 dependent with 10
L/min oxygen from a commercial concentrator.
Pilot Evaluation: The LeVe CPAP system was tested to evaluate safety and
acceptability in a group of ten healthy volunteers at Mengo Hospital in Kampala,
Uganda. The study demonstrated that the system can be used safely without inducing
hypoxia or hypercapnia and that its use was well-tolerated by users, with no adverse
events reported.
Conclusions: To provide respiratory support for the high patient numbers associated
with the COVID-19 pandemic, healthcare providers require resource efficient solutions.
We have shown that this can be achieved through frugal engineering of a CPAP ventilation
Culmer et al. The LeVe CPAP System
system, in a system which is safe for use and well-tolerated in healthy volunteers. This
approach may also benefit other respiratory conditions which often go unaddressed in
Low and Middle Income Countries (LMICs) for want of context-appropriate technology
designed for the limited oxygen resources available.
Keywords: CPAP, frugal innovation, respiratory support, medical devices, COVID-19
INTRODUCTION
The COVID-19 pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has placed a significant
demand on healthcare providers (HCPs) to provide respiratory
support for patients with moderate to severe symptoms (1).
Emerging clinical reports indicate that Continuous Positive
Airway Pressure (CPAP) non-invasive ventilation can help
patients with moderate symptoms to avoid the need for
invasive ventilation in intensive care (2, 3), a change to the
first impression that early intubation was indicated. Use of
CPAP has been proposed in this context because the positive
pressure can help address hypoxaemic respiratory failure,
opening the lungs to aid oxygen absorption in lungs which
remain compliant and recruitable (4). Regulatory authorities
such as the UK Medicines and Healthcare products Regulatory
Agency (MHRA) (5), US Food and Drug Administration
(FDA) (6) and World Health Organization (WHO) (7) have
produced guidance to support rapid development, manufacture
and approval of new ventilation systems which can be
produced at scale (8–10). However, the demand for ventilator
equipment is outstripping supply through complex international
supply chains (11). Similarly, the high patient numbers
presenting in a clinical setting has placed increased burden
on hospital resources and the provision of medical oxygen
crucial for ventilation has faced restrictions to avoid overloading
hospital systems (12).
The need to minimise oxygen consumption per patient and
reduce the complexity of equipment are paramount to consider
together, this has implications on adoption within different
healthcare contexts. Figure 1 uses these traits to classify the
types of system available for delivering CPAP in a healthcare
setting. The innovation to address provision as a result of
the COVID-19 pandemic has been impressive, particularly in
relation to systems using pressurised oxygen (the right hand
quadrants of Figure 1) typical of many healthcare systems
in high income countries (HICs). For example, the UCL-
Ventura device (mid-right quadrant) based on a Respironics
Whisperflow (14), has been licensed in excess of 1,000 times
(9). Whilst the focus of development was on rapid delivery,
the final device showed improved oxygen efficiency over its
initial design as a result of engineering changes. Venturi valves
(bottom right quadrant) are mechanically simple, have been
used extensively within healthcare settings to deliver CPAP,
and are readily scalable from a manufacturing standpoint. A
high pressure source of oxygen flows through the valve and
entrains air, creating a flow of enriched air at a modest pressure.
















Oxygen concentrator Bottled oxygen
~10 L/min~5 L/min
Low Pressure Source High Pressure Source
FIGURE 1 | Comparison of non-invasive ventilation options for delivering
CPAP arranged into quadrants according to their relative cost/complexity and
use of oxygen. The “resource light” quadrant (lower left) highlights the need for
systems which are both mechanically simple and can operate sustainably
using an oxygen concentrator with typical output flowrates (13).
oxygen) which allows clinicians to specify an appropriate valve
from a measurement of the patient’s oxygen saturation levels,
with pressure in the circuit controlled using a Positive End-
Expiratory Pressure (PEEP) valve design (15–17). Shortages of
these Venturi systems saw groups 3D printing such devices
on humanitarian grounds to support patient care (18, 19).
However, systems in both the right-hand quadrants require both
high flow and high pressure oxygen supply, in part because
this provides the energy to generate the pressure and flows
within the breathing circuit, rendering them incompatible with
oxygen concentrators.
In delivering CPAP, the nature of the oxygen supply in terms of
both the flow-per-patient and the delivery pressure is particularly
relevant within low-to-middle income countries (LMICs), where
limitations in healthcare infrastructure often precludes oxygen
delivery from a centralised, pressurised source. Instead, portable
oxygen concentrators provide a sustainable, reliable and cost-
effective solution (albeit at lower delivery pressures) in contrast
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to supply from compressed oxygen cylinders which require a
reliable supply infrastructure and continual monitoring (13, 20).
NGOs such as UNICEF have been provisioning LMICs with
oxygen concentrators for many years, recognizing the need for
oxygen therapies in general, which is also reflected in their
inclusion in theWHO list of essential medicines (21). The oxygen
concentrators appropriate for use in LMICs typically output at
low pressures and offer flow rates of 5 or 10 L/min with an oxygen
concentration of ca. 95% (13). Consequently, to deliver CPAP
using oxygen concentrators, systems must fall into the left-hand
side of Figure 1. Within the top left quadrant, non-invasive fan
based ventilator systems including sleep apnoea systems have
been used to successfully treat patients during the COVID-19
pandemic using oxygen entrained near the patient’s mask. These
have typically focused on treatment of patients with mild to
moderate requirements, thus low flow rates of oxygen are used
(ca. 5–10 L/min) to obtain 40–60% FiO2) (4, 22). This represents
the practical lower limit of oxygen consumption since below this,
treatment modalities tend to wean patients onto non-enriched
CPAP (i.e., no supplementary oxygen is provided) (4). The overall
flow rate of the enriched air supplied to the patient needs to
exceed at least 20 L/min (to avoid hypercapnia and maintain a
positive pressure during inspiration) (23) and in this treatment
context is more typically expected to be 60 L/min (24).
However, existing capabilities do not currently address the
bottom-left hand corner of Figure 1—we term solutions here
as LeVe (“light”)—CPAP systems with low complexity and high
resource efficiency—both from a design and oxygen supply (flow
rate and pressure) perspective. “Frugal innovation” provides
a development approach to target this region. Weyrauch and
Herstatt (25) define frugal innovation as one where products
have: (i) substantial cost reduction; (ii) concentration on core
functionalities; and (iii) optimised performance level. Our work
targets the development of systems that address the “resource
light” region, a neglected but important space to consider for
Global Health provision. Accordingly, here we report on the
development and initial evaluation of the LeVe CPAP Blower,
developed using frugal techniques to reduce the complexity
of fan based systems and focus specifically on providing
CPAP functionality.
SYSTEM DEVELOPMENT
To adapt CPAP technology into a low resource form, such
that it is appropriate for use in LMICs as well as other
resource-stretched situations, we hypothesise a design through
examination of the working principles within existing fan-based
non-invasive ventilators.
Existing Technology
Fan based ventilators use a modulated fan to control the output
pressure on a breathing circuit. The desired positive pressure is
maintained through a control loop, with an internal pressure
sensor used to set the appropriate fan speed. The breathing
circuit is shown in Figure 2. Of critical consideration is the need
to entrain oxygen close to the patient (between the mask and







FIGURE 2 | Schematic of a typical CPAP breathing circuit used for COVID-19
treatment (4). The CPAP machine is connected to an expiration port, a HEPA
filter, an oxygen inlet port, and the patient mask. The expiration port is a plain
hole: filtration of exhaled air before exhaust to atmosphere could prevent
aerosolization of disease carrying droplets.
an expiration port to prevent build-up of CO2. An example of a
commercial system is the Nippy 3+ (Breas Medical Ltd.), which
was adopted successfully within the Leeds Teaching Hospitals
NHS Trust to support COVID-19 patients. Such systems have
also been demonstrated in an open-source framework with a
low raw component cost although the expertise to assemble and
guarantee the quality of such a system is still relatively high
(25). The functionality of these devices is typically in excess of
that required to deliver CPAP therapy alone, systems typically
offer more complex breathing support including bi-level positive
airway pressure and automatic positive airway pressure. Since
adoption into a health care setting is not only about equipment
but also training of staff, this additional functionality may be
disabled to ensure healthcare compliance.
Requirements
To inform the development process of the LeVe system, our
target requirements were defined as delivery of CPAP at a mean
pressure of 10 cm H2O (1,000 Pa). The flowrate required to
maintain positive pressure is not set a priori, but determined
to ensure that the pressure remains positive for all parts of the
breathing cycle, nevertheless a typical guide value of 60 L/min
provided an initial starting point for a suitable flow (24). Within
this CPAP regime, the system should achieve a minimum 40%
FiO2 using an oxygen flow rate of 5 L/min (under normal
conditions) supplied at the modest delivery pressures that can be
achieved by oxygen concentrators (24); there is some variation
across concentrator models, widely used oxygen concentrators
such as the Phillips Everflow can be considered representative
and have outlet pressures of ca. 38 kPa (387 cm H2O) (26).
A general observation we have made is that it is not always
clear what conditions the flow rates are reported under; when
matching low pressure sources with CPAP devices, both the
pressure and the flow rate (at this pressure) are required. This
allows for total oxygen consumption to be compared (at some
defined standard air conditions, e.g., Normal Temperature and
Pressure 20◦C and 101.325 kPa) as well as establishing the
suitability of oxygen sources.
The heterogenous nature of healthcare settings means that
adoption of a specific technology requires local assessment
against availability of parts, manufacturing facilities and
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FIGURE 3 | The pressure response of the LeVe Blower with varying supply voltage for different simulated respiratory regimes. Each measurement point represents the
mean min/max pressure over 10 breathing cycles (defined as inspiration followed by expiration). Indicative standard error bars for these measures are indicated and
range from 0.14 to 0.29 cm H2O. Tidal Volumes (TV) of 500 and 250ml were simulated at 25 breaths per minute (BPM) and different inspiration:expiration (IE) ratios.
Connecting lines show the estimated response between measurement points using linear interpolation. Pressures are gauge pressures with sub-ambient pressures
recorded within the breathing circuit where inspiration rates are greater than the fan supply.
healthcare services. To support this, a wider discussion of overall
system requirements is included within this work.
Technical Approach
The LeVe CPAP Blower system is based on the premise that
a category of Brushless DC Current (BLDC) “fan blowers”
typically used for thermal management in electrical equipment
inherently have the flow dynamics required for provision of
CPAP, in general providing relatively high flow rates at low
but stable pressures. We propose a design compatible with
an oxygen concentrator which intrinsically drives an oxygen
efficient solution. Based on frugal engineering principles, the
design centers around an appropriately specified, single electric
fan-blower without the need for control features ofmore complex
fan-based CPAP systems. The resultant breathing circuit also
minimises the number of parts required for effective CPAP
since careful choice of the fan and the use of a simple
expiration port (which consists of a pipe section with a small
hole in the side—typically 4mm in diameter) means that
no PEEP valve (which brings greater complexity and cost)
is required.
We examined a range of BLDC fans capable of generating
pressures in the range of 12–20 cm H2O (1,200–2,000 Pa) at
flow rates of ∼100 L/min, thus ensuring the flow is greater
than the peak inspiratory flow rate to maintain continuous
positive pressure through the breathing cycle. By limiting the
peak delivery pressure in this selection ensures there is a degree
of safety for the patient should any speed regulation fail.
Two multinational manufacturers (selected to help ensure
supply-chain availability) supply models which fall within
these criteria [CUI Devices CBM-979533B-168 (peak pressure
1,325 Pa), Sanyo Denki San Ace B97 9BMB (peak pressure
1,280 Pa) and B97 9BMC (peak pressure 1,950 Pa)].
Of these possibilities, we selected the Sanyo Denki San Ace
9BMB model because it allows (equivalent) control of the fan
speed either by varying the supply voltage or by fixing this
and using a Pulse Width Modulation (PWM) control input (the
robust 555 timing chip can thus be used). The latter can reduce
system complexity and potential failure modes (in comparison to
directly varying the fan supply voltage). This model is available in
12 or 24 V models.
Figure 3 shows how a fan-blower based system can offer a
range of CPAP pressures through modulation of the fan speed
(Sanyo Denki San Ace 9BMB12P2K01, here with the speed varied
by changing the supply voltage). A breathing simulator, described
in Section 4, was used to obtain measures for two representative
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A The LeVe CPAP breathing circuit
FIGURE 4 | (A) The LeVe CPAP breathing circuit and (B) The complete LeVe system.
respiratory regimes. The characteristics show that the voltage
input to the fan controls the overall fan speed and consequently
the static pressure generated within the system. This offers the
ability to adjust the mask pressure by using a voltage regulator
to supply a variable supply voltage to the fan. In addition,
the minimum pressure differs between the respiratory regimes
because they impose different peak inspiratory flow rates (a
function of the Tidal Volume and Inspiration:Expiration ratio).
The fan cannot respond instantaneously to changes in flow rate
and consequently a pressure drop occurs. The inspiratory flow
rate is higher for the 500ml TV regime in comparison to the
250ml TV regime and consequently the minimum pressure is
lower. A working range can be defined between the maximum
operating speed and the point at which the fan cannot meet
the required flow rates. In this instance, below 7V the mask
pressure for the 500ml respiratory regime is negative; under such
a situation the instantaneous peak inspiratory flow rate is higher
than themaximumflow supplied by the fan, so a positive pressure
cannot be maintained (shown as a negative absolute pressure in
Figure 3).
System Design
The complete LeVe CPAP system was developed after selection
of the blower-fan to provide a robust package appropriate for
use in low-resource contexts by trained medical practitioners.
The system is designed around the fan blower, combined with
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FIGURE 5 | The breathing model and test configuration used to evaluate the LeVe systems. The pneumatic cylinder can be driven by the Universal Testing Machine to
simulate different respiratory regimes, as defined by Tidal Volume (TV), Breaths per Minute (BPM) and the Inspiration:Expiration ratio (I:E). All data were logged to the
data acquisition system (DAQ).
TABLE 1 | Respiratory regimes used to evaluate the LeVe system defined by the simulated lung parameters Tidal Volume (TV), Breaths per Minute (BPM) and
Inspiration:Expiration (I:E) ratio (the time taken for each phase of the breathing cycle).
Respiratory regime TV (ml) BPM I:E ratio Reference
(1) (Baseline) 500 25 1:2 Brusasco (24)
(2) (Modified baseline) 500 25 1:1.5 –
(3) 500 20 1:1.5 Schneider, Wilkins (30, 31), UK MHRA (5)
(4) 250 40 1:1 Kallet et al. (32)
a standard breathing circuit, in the configuration shown in
Figure 4. In this design, rather than controlling through a
supply voltage, the fan speed is controlled through a pulse-width
modulated signal, generated using robust 555 timing chips on a
low-cost PCB, which provides a low-voltage control frequency
directly to the fan. A four-way dial allows selection of nominal
CPAP pressures of 5, 7.5, 10, and 12.5 cm H2O, selected to match
typical requirements in COVID-19 treatment and with an upper
limit advised by our clinical team (27). Power is provided to
the selected fan (9BMB24P2K01) through a medical grade 24V
powerpack, which accepts a wide input voltage of 80–264V
AC. We note that a reduced part count could be achieved by
connecting the fan directly to 24V (for this fan model) to give
a fixed CPAP pressure of 12.5 cm H2O. A single switch on the
DC circuit allows the unit to be turned on and off. An intake
filtre is provided to prevent particulate material entering the fan
unit. The LeVe CPAP breathing circuit integrates the LeVe flow
generator, to give an oxygen efficient breathing circuit, as shown
Figure 4A. The breathing circuit has a dead space of ∼320ml
(comprising the volume of the mask and breathing circuit up
to the expiratory port). The breathing circuit was implemented
under the guidance of the clinical team within the Leeds NHS
Teaching Hospital Trust and Bradford NHS Teaching Hospital
Trust for treatment of patients with Covid-19 and adopted
nationally within the UK (4, 28).
From the LeVe flow generator, there will be a constant flow of
air through the expiration port. During inspiration, a fraction of
air is drawn from this flow toward the patient and this oxygen is
entrained into this fraction. This mechanism ensures enrichment
of just the air breathed by the patient rather than requiring
the entire airflow to be enriched at source. Exhaled air passes
out of the exhalation port, together with some oxygen, which
represents a small inefficiency within the circuit. However, the
overall oxygen efficiency is still high, particularly compared to
systems like Venturi devices which typically use over 15 L/min
oxygen from a high pressure (3–4 bar) mains source to achieve
a working pressure of 10 cm H2O (24, 29). The ultimate FiO2 is
then be controlled by varying the flow rate of the oxygen source
appropriately. It is important to note that this is intended to be
performed by a trained clinician informed by oxygen saturation
readings [as performed for similar CPAP systems in clinical
use (4)].
SYSTEM EVALUATION
The fundamental performance characteristics of a CPAP system
can be measured through: (i) the pressure at the patient mask
during a breathing cycle; and (ii) the FiO2 of inspired air
for a given oxygen flow rate. These aspects were investigated
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in controlled laboratory conditions to ensure appropriate
performance prior to human use.
Methods
To measure the flow dynamics of the system in a controlled
and repeatable manner, a breathing simulator was developed.
The simulator, summarised in Figure 5, consisted of a large bore
pneumatic cylinder (SMC CQ2 Series, 160mm diameter) driven
by a dynamic testing machine (Electro Puls E10000, Instron)
which allows the cylinder piston to be moved under a pre-defined
cyclic pattern, facilitating a variety of respiratory regimes (see
Figure 5, inset, for example) to be tested. The rigid cylinder
removes the effect of lung compliance on the simulations but
enables the impact of breathing patterns to be assessed in terms
of oxygen efficiency and pressure response of the circuit. Four
different respiratory regimes were used (Table 1) to represent a
spread of respiratory cases, from slow deep breathing in healthy
adults tomore rapid shallow breathing associated with conditions
like COVID-19 (33).
Key parameters measured within the system were mask
pressure (IPSU-M12, RS), outlet flowrate of the blower
(SFM3300, Sensiron), and oxygen concentration in the mask
(Max-550E, Maxtec). Pressure and flowrate data were logged
using a data acquisition system (cRIO, National Instruments)
at 200Hz whilst the oxygen concentration was recorded once a
steady state was reached. In each configuration, measurements
were averaged over 10 cycles. Oxygen was supplied using
a concentrator (Drive 10 L/min DeVilbiss Healthcare). Each
system was connected to the breathing simulator using standard
medical-grade components.
Results
Figure 6 shows a comparison of the mask pressure achieved
for two respiratory regimes with the LeVe system and the
commercial Nippy 3+, both configured to provide 10 cm H2O.
In general, a drop in pressure is observed during inspiration as
air is drawn from the breathing limb, and a rise observed during
expiration. For the baseline respiratory regime 1 (see Table 1)
the RMS pressure of the LeVe system is 9.76 cm H2O (2.4%
error), in comparison the Nippy 3+ achieves 9.32 cm H2O (6.8%
error). Across the breathing cycle the pressure range of the LeVe
is 7.04 cm H2O and for the Nippy 3+ is 7.29 cm H2O. These
characteristics are similar to those recorded for other commercial
and open source CPAP systems (34).
Figure 6C presents a summary box plot indicating the
median, upper, and lower quartile as well as the maximum
and minimum values. Unsurprisingly, given the observations in
Figures 6A,B, the pressure characteristics for the two systems are
comparable with respect to their median pressure and overall
operating range. The pressure range is affected by the respiratory
regime since this defines the peak inspiration flow rates. For
example, the LeVe system produced a pressure range of 7.04 cm
H2O (Regime 1) and 4.32 cmH2O (Regime 4). It should be noted
that pressures remained positive in all cases, which is important
to ensure the lungs remain open.
Figure 7 illustrates the oxygen efficiency of the LeVe system
alongside that of the Nippy 3+. In terms of oxygen performance,
the Nippy 3+ was found to have a slightly higher efficiency
(i.e., the FiO2 achieved for a given oxygen supply flowrate)
than the LeVe system. More significantly, the respiratory regime
has an effect on oxygen performance, in particular lower
peak inspiration rates (lower breaths per minute, smaller tidal
volumes, and/or lower I:E ratios) resulting in increased efficiency
and a reduction in the difference between systems. In both
systems, the maximum FiO2 that can be achieved at 10 L/min O2
(i.e., the limit of a typical oxygen concentrator) ranges from ca.
50 to 55% (TV = 500ml, 25 bpm, I:E 1:2) to 70% (TV = 250ml,
40 bpm, I:E 1:1.5).
PILOT STUDY
A pilot study was conducted to evaluate the safety and
acceptability of the LeVe CPAP Flow Generator in a group of
healthy volunteers at Mengo Hospital in Kampala, Uganda. Two
research questions were set:
Primary: Can the LeVe CPAP Flow Generator be used safely
without inducing hypoxia or hypercapnia? Secondary: Is the
LeVe CPAP Flow Generator well-tolerated by users?
The healthy participants in the study are likely to present
with lungs with normal lung compliance. While this does not
necessarily replicate the lung condition of those with COVID-
19 (the motivation for this work) it is a necessary first stage
in demonstrating that the system can provide a safe and
tolerable intervention.
Methods
This study took place in the Intensive Care Unit at Mengo
Hospital, Kampala, Uganda. A sample of 10 participants was
recruited, all of whom were members of staff at the hospital.
All participants were provided with a written information
sheet, gave informed written consent and were not offered
any financial incentive to participate in the study. Approval
was obtained from the Mengo Hospital Research and Ethics
Committee (M 02/01-2021) and the Uganda National Council
for Science and Technology (HS1250ES). The protocol was
registered and approved by the Pan African Clinical Trials
Registry (PACTR202105734146484), a summary of key aspects
is as follows. The inclusion criteria were for participants to
be staff members at Mengo Hospital aged 20–50 years with
no involvement in the research study. The key exclusion
criteria were:
• Current or ex-smoker
• Underlying respiratory conditions
• BMI > 30
• Any contraindications from previous use of CPAP or
oxygen therapy.
The participants first trialled the mask to assess the fit. After
taking a baseline reading, the LeVe CPAP Flow Generator
was switched on and the pressure was stepped through the 4
pressure settings (5, 7.5, 10, and 12.5 cm H2O). A commercially
available oxygen concentrator was connected to the breathing
circuit (as shown in Figure 4) to enrich the air supply with
5 L/min oxygen. The participants’ oxygen saturation (SpO2)
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FIGURE 6 | Typical pressure response characteristics of the LeVe system and a commercial sleep apnea CPAP system (Nippy 3+), configured to generate 10 cm
H2O (Indicated by black dotted line) shown for different respiratory regimes, defined by Tidal Volume (TV), Breaths per Minute (BPM), and Inspiration:Expiration ratio
(I:E). Parts (A,B) show representative pressure waveforms for two contrasting respiratory regimes, (C) provides a boxplot summary of the pressure characteristics
across all respiratory regimes defined in Table 1.
and end tidal CO2 (ETCO2) level were monitored continuously
throughout the study. Oxygen saturation was measured by a
pulse oximeter (Mindray VS900) with finger attachment, ETCO2
using a capnograph with the sample line attached to a port
on the face mask. Hypoxia was defined as oxygen saturations
< 94% and hypercapnia was defined as ETCO2 > 5.7 kPa
(35). The null-hypothesis was no difference in oxygen saturation
across the five groups represented by the four CPAP values and
the baseline measurement. A one-way ANOVA was undertaken
with a post-hoc assessment of pairwise evaluations using the
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Regime 1
(TV:500ml, 25bpm, 1:2 I:E)
Regime 4
(TV:250ml, 40bpm, 1:1.5 I:E)
Regime 2
(TV:500ml, 25bpm, 1:1.5 I:E)
Regime 3
(TV:500ml, 40bpm, 1:1.5 I:E)
FIGURE 7 | FiO2 characteristics of the LeVe breathing circuit in comparison to a sleep apnea CPAP system (Nippy 3+) under different respiratory regimes defined by
Tidal Volume (TV), Breaths per Minute (BPM), and Inspiration:Expiration ratio (I:E). Oxygen flow rates reported under NTP.
Bonferroni Correction to account for multiple comparisons. The
participants were then provided with a questionnaire which
asked them to rate overall comfort, anxiety, claustrophobia, and
difficulty in breathing using a Likert scale to assess each attribute.
This was adapted from a similar study (36) and is available in
Supplementary Materials.
Results
In total, 10 participants were recruited. Mean age was 24.9
years (range 22–30 years) and 50% were female. Measured data
for end-tidal CO2 and oxygen saturation levels is provided in
Table 2. Data were recorded successfully for all participants with
the exception of two readings at 5 cm H2O for participants
9 and 10 due to a reading error at this setting. Overall, the
results demonstrate a consistent and desirable positive response
in oxygen saturation levels of 96–100% SpO2 (37) across all
participants, within accepted healthy limits. Similarly, end tidal
CO2 ranges between 3.6 and 4.9 kPa across the participants, all
below the 5.7 kPa threshold that was defined as hypercapnia (35).
Figure 8 shows the average oxygen saturation levels for
the participants as a function of the nominal CPAP setting.
The ANOVA revealed a rejection of the null-hypothesis (P
= 0.0002) across the five groups with significant pairwise
comparisons noted for both groups as denoted by CPAP
values of 10 and 12 cm H2O when compared with the base
readings in the absence of CPAP. This indicates a small but
detectable improvement in oxygen saturation in participants
with healthy lungs at the two highest values of CPAP
pressure, potentially because this acts to reduce the physiological
shunt. However, this outcome requires further study in a
non-healthy population before any clinical significance can
be attributed.
In terms of tolerability, overall comfort was measured on
a scale of 1–5 where 1 indicated “not at all comfortable” and
5 indicated “very comfortable.” Figure 9 demonstrates user
tolerability of the device with the mean response and standard
error also shown. Mean overall comfort level was 4.4. Anxiety,
claustrophobia, and difficulty in breathing were then measured
on a scale of 1–5 where 1 indicated “not at all” and 5 indicated
“strongly.” Mean anxiety level was 2.1, mean claustrophobia
level was 1.5, and mean difficulty in breathing level
was 1.9.
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TABLE 2 | Oxygen saturation and end-tidal CO2 levels across the cohort (MD, Missing data due to reading error).
Participant % Oxygen saturation Maximum ETCO2 (kPa)
CPAP setting (cm H2O)
0 5 7.5 10 12
1 97 98 98 98 98 3.6
2 97 98 98 98 98 4.8
3 98 98 98 99 100 4.6
4 98 98 98 98 98 4.3
5 97 98 99 99 99 4.8
6 96 95 98 98 98 4.6
7 96 98 98 98 98 3.9
8 96 96 98 98 99 3.9
9 97 MD 98 99 99 4.5
10 97 MD 96 98 98 4.9
Mean 96.9 97.4 97.9 98.3 98.5 4.4
FIGURE 8 | Box and whisker plot showing mean oxygen saturation levels as a
function of CPAP levels for the 10 participants. N = 10 for Baseline, 7.5, 10,
12.5 cm H2O; N = 8 for 5 cm H2O (due to missing data).
DISCUSSION
The LeVe Blower is a simple system, deliberately developed
to provide a low resource solution for the provision of CPAP
ventilation in terms of oxygen requirements, power, and ease-
of use whilst not sacrificing performance. Following frugal
engineering principles, the systems have been developed to
meet a focussed set of requirements while removing extraneous
functionality and thus complexity. For example, while open-
sourced CPAP systems have been developed to provide low-
cost alternatives to commercial systems, they fundamentally
share a common approach in using microprocessor systems
to regulate their output (34). In contrast, the LeVe system
uses the inherent flow characteristics of the fan to achieve
comparable performance in terms of RMS pressure (e.g., 10 cm
H2O target pressure within 2.4% RMS error) and 50–70% FiO2
over representative respiratory regimes, despite their lack of
closed-loop pressure regulation. This has a small impact on
oxygen performance (shown in Figure 7) because the open-loop
fan control reduces the fraction of exhaled air that is rebreathed
and that which leaves the system, hence it achieves marginally
lower FiO2 for a given oxygen supply flowrate. Considering
resource efficiency, the LeVe system is designed to generate
a pressurised airflow without the use of compressed oxygen,
which is typically a limited commodity in LMICs, instead relying
on more prevalent and sustainable electrical power (13, 26).
This approach enables the system to achieve high efficiency in
the supply of oxygen-enriched air and allows oxygen delivery
to be controlled independently of the desired CPAP operating
pressure. In the case of LMIC context, this enables the use of
oxygen concentrators as a supply.
Selection of an appropriate CPAP system for clinical use
is heavily dependent on the environment, infrastructure, and
resources present. Reflecting on Figure 1, our focus has been
to target “resource-light” solutions, to ensure that they are
appropriate for LMIC contexts. This goes beyond producing
a “low-cost” system, instead frugal engineering emphasises the
need for systems which consider manufacture, sustainable long-
term use and crucially does not sacrifice performance to achieve
these goals. The LeVe system is designed to operate using an
oxygen concentrator to enrich the air supply. Typically, these are
available in 5 or 10 L/min where the output of the latter can be
split with 2 flow regulators to treat two patients to achieve∼40%
FiO2. This provides a scalable and resource-efficient solution
to cater for varying patient numbers. In contrast, operating
conventional Venturi valve systems, which fall in the lower
right quadrant of Figure 1 (and therefore have a cost/complexity
profile appropriate for LMIC), would require provision of
compressed oxygen at high flow rates which is challenging to
achieve in many LMICs without recourse to repeated changeover
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FIGURE 9 | User tolerability of device. Perceptions of users during CPAP delivery using LeVe. Error bars indicate ±1 SD. 5: Very high, 4: High, 3: Moderate, 2: Low,
and 1: Very low.
of oxygen cylinders, a practise which is both costly and demands
regular maintenance support (38).
The results of the study demonstrate that in a healthy cohort,
the LeVe system is safe for use and well-tolerated by the
participants. Measures of oxygen saturation demonstrate that the
system does not induce hypoxia or reduce oxygen saturation,
and in fact it may actually increase saturation levels. In a fit and
well-population, the significance of any increase in SpO2 with
CPAP was likely to be minimal. Similarly, measures of end tidal
CO2 show that LeVe does not cause hypercapnia. The ultimate
FiO2 delivered by any CPAP system varies with respiratory
function and is not explicitly controlled. Thus, these systems
require external monitoring by a suitably qualified healthcare
professional based upon the patient’s SpO2 level and vital signs in
accordance with best practise (e.g., UK MHRA guidance). This
places an emphasis on the need to accompany such systems with
appropriate training and clinical use protocols to ensure quality
of care.
Considering comfort, it is important to note that the provision
of positive pressure through a face mask will inherently impact
on “natural” inhalation and expiration, thus may cause anxiety
and discomfort, regardless of the air source (39). Within the
scope of this study, it indicates that the air pressure and flow
characteristics of the LeVe system, in particular the inherent
variability which occurs during the breathing cycle, are both
tolerated and appropriate for future clinical evaluation. In
conjunction, the high comfort rating reported for the mask is
integral to the overall experience and should be carefully selected
to ensure a close but comfortable fit.
Research has shown how the clinical efficacy of CPAP
systems has evolved rapidly during the COVID-19 pandemic
(3). Particularly in LMIC contexts, the utility of CPAP is likely
to have increasing relevance to treatment of other conditions,
particularly when more advanced forms of ventilation are not
available. For example, CPAP provides a route to stabilise patients
with acute pulmonary oedema whilst the underlying cause is
being treated (40). Similarly, based on the success of using
CPAP to treat COVID-19, it could be explored for treatment of
conditions like viral pneumonias or severe influenza. This need
not be confined to acute settings, there is scope to explore the
use of simple devices like LeVe for early presentation of COVID-
19 within community settings, helping to reduce the burden on
hospital admissions. Last, but not least, it is also interesting to
note that while these systems were developed to target use in
LMICs, there is increasing recognition of the need to innovate for
value within the resource-strained healthcare systems of HICs.
Often termed “reverse innovation,” there is also potential for the
use of low-resource CPAP systems within services like the UK’s
NHS (41, 42).
CONCLUSIONS
CPAP ventilation systems provide an important treatment
option for COVID-19 patients, particularly in the early stages
before invasive ventilation strategies are required, to deliver
oxygen-enriched air to stabilise patients until they can be
escalated or de-escalated. To deliver this for the high patient
numbers associated with the COVID-19 pandemic, healthcare
providers require resource efficient solutions. We have shown
that this can be achieved through frugal engineering of a CPAP
ventilation system.
The data from the pilot study indicate that the LeVe CPAP
Flow Generator is safe to use in healthy volunteers and was
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well-tolerated by the cohort. This solution has different merits
in clinical performance and efficiency to existing CPAP systems
but provides resource-limited healthcare providers with a more
resource-efficient solution to support flexible treatment pathways
that can be rapidly deployed to reduce the burden on ICU
during the COVID-19 pandemic. Beyond this immediate need,
there is also evidence that CPAP can help provide much needed
therapeutic benefit to address other respiratory conditions (e.g.,
respiratory distress syndrome) which often go unaddressed in
LMICs for want of context-appropriate technology.
Our ambition is that this work will support the treatment
of patients suffering from COVID-19 and (beyond the current
pandemic) expand treatment options available to healthcare
professionals targeting respiratory distress syndromes. Our
ongoing work will build on these foundations; firstly by
evaluating the clinical efficacy of using the LeVe system to
provide respiratory support in patients with COVID-19, secondly
by exploring opportunities to make the technology commercially
available, coupled with the requisite regulatory approval, for use
in LMIC settings.
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